Skip to main content

Advertisement

Table 1 Patients’ baseline characteristics

From: Clinical efficacy of adalimumab in Crohn’s disease: a real practice observational study in Japan

Patient number 62
Age (years) 33.1 ± 10.3
Gender (male) 74.2 % (46/72)
Disease duration (months) 96.0 (0.0–480.0)
Disease duration < 2 years 32.3 % (20/62)
Disease location  
 Ileo 14.5 % (9/62)
 Ileocolonic 74.2 % (46/62)
 Colonic 11.3 % (7/62)
Surgery required 62.9 % (39/63)
Extra fistula 34.4 % (21/61)
Intra fistula 8.2 % (5/61)
Perianal disease 48.4 % (30/62)
Smoking 17.3 % (9/52)
Concomitant use  
 5-Aminosalicylates 91.9 % (57/62)
 Steroids 9.7 % (6/62)
 Immunomodulators 24.2 % (15/62)
 Elemental diet 62.9 % (39/62)
IFX experience  
 Experience with IFX 53.2 % (33/62)
 Double dose 33.3 % (11/33)
 Duration of IFX use (months) 19.0 (1.0–100)
 Reason for switching  
  PNR 6.3 % (2/32)
  SNR 46.9 % (15/32)
  Intolerance 43.8 % (14/32)
  Others 3.1 % (1/32)
Baseline CDAI (points) 185.1 ± 76.4
Baseline CRP (mg/dL) 0.74 (0.00–6.86)
  1. Parametric variables are shown as mean ± standard deviation or median (range)
  2. IFX infliximab, PNR primary nonresponse, SNR secondary nonresponse, CDAI Crohn’s Disease Activity Index, CRP C-reactive protein